p66Shc mediates SUMO2-induced endothelial dysfunction.
5 affiliations
- 1Department of Internal Medicine, Division of Cardiovascular Medicine, University of Iowa, Iowa City, United States.
- 2Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, United States.
- 3Genome Editing Core Facility, University of Iowa, Iowa City, United States.
- 4Regional Institute of Education-NCERT, Mysore, India.
- 5Department of Biochemistry and Molecular Biotechnology, Mass Spectrometry Facility, University of Massachusetts Chan Medical School, Worcester, United States.
Abstract
Sumoylation is a post-translational modification that can regulate different physiological functions. Increased sumoylation, specifically conjugation of SUMO2/3 (small ubiquitin-like modifier 2/3), is detrimental to vascular health. However, the molecular mechanism mediating this effect is poorly understood. We used cell-based assays and mass spectrometry to show that p66Shc is a direct target of SUMO2 and that SUMO2 regulates p66Shc function via lysine-81 modification. To determine the effects of SUMO2-p66ShcK81 on vascular function, we generated Shc1K81R mice and crossbred them toLdlr-/- mice to induce hyperlipidemia. Next, to determine p66ShcK81-SUMO2ylation-induced changes in endothelial cell signaling, we performed mass spectrometry followed by Ingenuity Pathway Analysis. Our data reveal that p66Shc mediates the effects of SUMO2 on endothelial cells. Mass spectrometry identified that SUMO2 modified lysine-81 in the unique collagen homology-2 domain of p66Shc. SUMO2ylation of p66Shc increased phosphorylation at serine-36, causing it to translocate to the mitochondria, a step critical for the oxidative function of p66Shc. Notably, sumoylation-deficient p66Shc (p66ShcK81R) was resistant to SUMO2-induced p66ShcS36 phosphorylation and mitochondrial translocation. Shc1K81R mice were resistant to endothelial dysfunction induced by SUMO2ylation and hyperlipidemia. Ingenuity Pathway Analysis revealed multiple signaling pathways regulated by p66ShcK81-SUMO2ylation in endothelial cells, highlighting JAK-STAT as a major pathway affected by SUMO2-p66ShcK81. Collectively, our work reveals SUMO2-p66Shc signaling as a fundamental regulator of vascular endothelial function. We discovered that p66ShcK81 is an upstream modification regulating p66Shc signaling and mediates hyperlipidemia-induced endothelial dysfunction and oxidative stress.
Related
- H3K18la- driven neutrophil secretory autophagy promotes pulmonary endothelial dysfunction in sepsis-induced lung injury
- IGFBP2 attenuates high glucose-induced endothelial dysfunction through PI3K/Akt/eNOS pathway activation
- Endothelial miR‐15a/16‐1 Regulation of SYNE1 Mediates Structural and Functional Recovery after Traumatic Brain Injury
- Immune Consequences of Endothelial Cells’ Activation and Dysfunction During Sepsis
- Sepsis-associated endothelial dysfunction: clinical phenotypes, biomarkers, bedside evidence, and translational implications
BibTeX
@article{kumar2026p66shc,
title = {{p66Shc mediates SUMO2-induced endothelial dysfunction.}},
author = {Jitendra Kumar and Shravan K Uppulapu and Sujata Kumari and Kanika Sharma and William J Paradee and Ravi Prakash Yadav and Vikas Kumar and Santosh Kumar},
journal = {ELife},
year = {2026},
month = oct,
doi = {10.7554/elife.106344},
url = {https://europepmc.org/article/MED/42905449},
note = {CC BY},
}
RIS
TY - JOUR
TI - p66Shc mediates SUMO2-induced endothelial dysfunction.
AU - Jitendra Kumar
AU - Shravan K Uppulapu
AU - Sujata Kumari
AU - Kanika Sharma
AU - William J Paradee
AU - Ravi Prakash Yadav
AU - Vikas Kumar
AU - Santosh Kumar
PY - 2026
DA - 2026/10/21
JO - ELife
DO - 10.7554/elife.106344
UR - https://europepmc.org/article/MED/42905449
AB - Sumoylation is a post-translational modification that can regulate different physiological functions. Increased sumoylation, specifically conjugation of SUMO2/3 (small ubiquitin-like modifier 2/3), is detrimental to vascular health. However, the molecular mechanism mediating this effect is poorly understood. We used cell-based assays and mass spectrometry to show that p66Shc is a direct target of SUMO2 and that SUMO2 regulates p66Shc function via lysine-81 modification. To determine the effects of SUMO2-p66ShcK81 on vascular function, we generated Shc1K81R mice and crossbred them toLdlr-/- mice to induce hyperlipidemia. Next, to determine p66ShcK81-SUMO2ylation-induced changes in endothelial cell signaling, we performed mass spectrometry followed by Ingenuity Pathway Analysis. Our data reveal that p66Shc mediates the effects of SUMO2 on endothelial cells. Mass spectrometry identified that SUMO2 modified lysine-81 in the unique collagen homology-2 domain of p66Shc. SUMO2ylation of p66Shc increased phosphorylation at serine-36, causing it to translocate to the mitochondria, a step critical for the oxidative function of p66Shc. Notably, sumoylation-deficient p66Shc (p66ShcK81R) was resistant to SUMO2-induced p66ShcS36 phosphorylation and mitochondrial translocation. Shc1K81R mice were resistant to endothelial dysfunction induced by SUMO2ylation and hyperlipidemia. Ingenuity Pathway Analysis revealed multiple signaling pathways regulated by p66ShcK81-SUMO2ylation in endothelial cells, highlighting JAK-STAT as a major pathway affected by SUMO2-p66ShcK81. Collectively, our work reveals SUMO2-p66Shc signaling as a fundamental regulator of vascular endothelial function. We discovered that p66ShcK81 is an upstream modification regulating p66Shc signaling and mediates hyperlipidemia-induced endothelial dysfunction and oxidative stress.
SN - 2050-084X
ER -